Aberdeen Group plc Has $47.27 Million Stock Position in Ascendis Pharma A/S $ASND

Aberdeen Group plc boosted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 348.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 221,677 shares of the biotechnology company’s stock after purchasing an additional 172,251 shares during the period. Aberdeen Group plc owned about 0.36% of Ascendis Pharma A/S worth $47,270,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Advisory Services Network LLC acquired a new stake in Ascendis Pharma A/S in the third quarter valued at about $26,000. Jones Financial Companies Lllp lifted its holdings in shares of Ascendis Pharma A/S by 57.2% in the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the last quarter. Quadrant Capital Group LLC bought a new position in shares of Ascendis Pharma A/S in the third quarter worth about $74,000. Farther Finance Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 115.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 256 shares in the last quarter. Finally, Toth Financial Advisory Corp boosted its stake in shares of Ascendis Pharma A/S by 33.7% in the 3rd quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 150 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms recently issued reports on ASND. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, January 21st. Wedbush boosted their target price on shares of Ascendis Pharma A/S from $240.00 to $273.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Wells Fargo & Company upped their price target on shares of Ascendis Pharma A/S from $322.00 to $330.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Stifel Nicolaus set a $332.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, March 4th. Finally, Evercore reiterated an “outperform” rating and issued a $324.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $289.89.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $229.25 on Friday. Ascendis Pharma A/S has a 52-week low of $124.06 and a 52-week high of $248.60. The firm has a 50 day moving average price of $227.16 and a two-hundred day moving average price of $213.91. The stock has a market cap of $14.29 billion, a P/E ratio of -52.10 and a beta of 0.49.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.58). The firm had revenue of $290.38 million for the quarter, compared to the consensus estimate of $285.35 million. Analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.